Managing Principal Anita Chawla Discusses the Commercialization of Personalized Medicine

September 16, 2014

In the keynote panel at The Business of Personalized Medicine Summit in San Francisco on September 9, 2014, Analysis Group Managing Principal Anita Chawla discussed the challenges of meeting reimbursement requirements associated with demonstrating clinical utility and economic value, while maintaining a sustainable business strategy, in commercializing personalized medicine and molecular diagnostics. In the discussion, Dr. Chawla noted that success depends on providing an appropriate level of information to regulatory authorities and payers. For more novel diagnostic tests, this evidence threshold is much higher than for more established diagnostic tests. Other participants agreed with Dr. Chawla's assessment and stressed the importance of data in an era of limited financial resources.

The panel discussion, "Health Care Economics & Implications of Personalized Medicine," also featured experts from Foley & Lardner LLP, Janssen Diagnostics, and Centers for Medicare & Medicaid Services (CMS) and was the second session of the event, which was co-hosted by the Personalized Medicine Coalition and Foley & Lardner LLP.

Read more about the event